Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab versus cyclophosphamide for refractory uveitis in Behcet disease
IRCT20180110038297N1Phase 3Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Mar 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab and cyclophosphamide in Behçet's disease (BD) and uveitis (2 arms), sponsored by Zanjan University of Medical Sciences. Primary endpoints: Total inflammatory activity index and Inflammatory activity index with visual acuity. Started Mar 2017; status: completed.
02
Drugs
infliximabcyclophosphamide
03
Conditions
Behçet's disease (BD)uveitis
Beyond the preview
Go deeper on IRCT20180110038297N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180110038297N1.